Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $32.60.

A number of research firms have weighed in on SLN. Wall Street Zen upgraded Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors have recently added to or reduced their stakes in SLN. Cantor Fitzgerald L. P. increased its stake in shares of Silence Therapeutics by 1.6% during the third quarter. Cantor Fitzgerald L. P. now owns 801,306 shares of the company’s stock valued at $4,159,000 after buying an additional 12,267 shares during the period. Millennium Management LLC boosted its holdings in Silence Therapeutics by 50.3% in the third quarter. Millennium Management LLC now owns 298,512 shares of the company’s stock valued at $1,549,000 after acquiring an additional 99,865 shares in the last quarter. Citadel Advisors LLC purchased a new position in Silence Therapeutics during the 3rd quarter valued at $112,000. Boothbay Fund Management LLC raised its holdings in Silence Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 279,637 shares of the company’s stock worth $1,451,000 after purchasing an additional 27,216 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Silence Therapeutics by 6.6% in the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after purchasing an additional 3,935 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Down 9.4%

Shares of NASDAQ SLN opened at $5.04 on Friday. The company has a market cap of $238.04 million, a P/E ratio of -3.73 and a beta of 1.32. Silence Therapeutics has a 52 week low of $1.97 and a 52 week high of $7.78. The business has a 50-day simple moving average of $6.30 and a two-hundred day simple moving average of $5.96.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $3.28 million. Equities research analysts anticipate that Silence Therapeutics will post -1.77 EPS for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.